Vishal Manchanda
Long/short equity, deep value, special situations, contrarian

Sell Ranbaxy - Recent Run Up Provides An Opportunity For Investors To Exit

The stock price of Ranbaxy (OTC:RBXLY), subsidiary of Japan based Daiichi Sankyo (OTCPK:DSKYF) is up 30 percent over the last 3 months (as against 13.1% by other specialty generic companies) and I believe this is an opportune time for investors to cash in. The run up is in expectation of a turnaround driven by a few first to file (NYSEMKT:FTF) generic drug launches (Nexium and Valcyte generics) and upside from a strong ramp up of its acne drug Absorica (Isotretinoin) in the US. I believe there is over optimism surrounding the stock and it makes sense to exit,

· There is a strong chance that Ranbaxy may not be able to capitalize on these...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details